A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT ID: NCT06993792
Last Updated: 2025-11-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
1200 participants
INTERVENTIONAL
2025-05-15
2027-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SCREENING
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Orforglipron Dose 1 (Study GZP1)
Participants will receive orforglipron orally
Orforglipron
Administered orally
Orforglipron Dose 2 (Study GZP1)
Participants will receive orforglipron orally
Orforglipron
Administered orally
Orforglipron Dose 3 (Study GZP1)
Participants will receive orforglipron orally
Orforglipron
Administered orally
Orforglipron Dose 4 (Study GZP1)
Participants will receive orforglipron orally
Orforglipron
Administered orally
Placebo (Study GZP1)
Participants will receive placebo orally
Placebo
Administered orally
Orforglipron Dose 1 (Study GZP2)
Participants will receive orforglipron orally
Orforglipron
Administered orally
Orforglipron Dose 2 (Study GZP2)
Participants will receive orforglipron orally
Orforglipron
Administered orally
Orforglipron Dose 3 (Study GZP2)
Participants will receive orforglipron orally
Orforglipron
Administered orally
Orforglipron Dose 4 (Study GZP2)
Participants will receive orforglipron orally
Orforglipron
Administered orally
Placebo (Study GZP2)
Participants will receive placebo orally
Placebo
Administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Orforglipron
Administered orally
Placebo
Administered orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* See study GZP1 for eligibility criteria relevant to participants with obesity and overweight without type 2 diabetes
* See study GZP2 for eligibility criteria relevant to participants with type 2 diabetes
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research Institute of Arizona (CRI) - Sun City West
Sun City West, Arizona, United States
Novak Clinical Research - Tucson - North La Cholla Boulevard
Tucson, Arizona, United States
Norcal Endocrinology & Internal Medicine
San Ramon, California, United States
Southern California Clinical Research
Santa Ana, California, United States
Care Access - Thousand Oaks
Thousand Oaks, California, United States
Accel Research Sites - DeLand Clinical Research Unit
DeLand, Florida, United States
Innovation Medical Research Center - Fort Lauderdale
Fort Lauderdale, Florida, United States
Indago Research & Health Center, Inc
Hialeah, Florida, United States
Encore Medical Research
Hollywood, Florida, United States
West Orange Endocrinology P.A.
Ocoee, Florida, United States
Care Access - Tampa
Tampa, Florida, United States
Accel Research Sites - NeuroStudies Clinical Research Unit
Decatur, Georgia, United States
Care Access - Decatur
Decatur, Georgia, United States
Javara - Privia Medical Group Georgia - Savannah
Savannah, Georgia, United States
North Georgia Clinical Research
Woodstock, Georgia, United States
Solaris Clinical Research
Meridian, Idaho, United States
Care Access - New Iberia
New Iberia, Louisiana, United States
Endocrine and Metabolic Consultants
Rockville, Maryland, United States
Javara - Privia Medical Group - Silver Spring
Silver Spring, Maryland, United States
Boeson Research MSO
Missoula, Montana, United States
Javara - Nevada Health Centers - Carson City
Carson City, Nevada, United States
The Machuca Foundation
Las Vegas, Nevada, United States
University of North Carolina Medical Center
Chapel Hill, North Carolina, United States
Javara - Tryon Medical Partners
Charlotte, North Carolina, United States
Care Access - Fayetteville
Fayetteville, North Carolina, United States
The Corvallis Clinic, P.C.
Corvallis, Oregon, United States
Clinical Research of Philadelphia
Philadelphia, Pennsylvania, United States
Frontier Clinical Research, LLC
Smithfield, Pennsylvania, United States
Velocity Clinical Research, Dallas
Dallas, Texas, United States
Biopharma Informatic, LLC
Houston, Texas, United States
Texas Valley Clinical Research (TVCR) - Mission
Mission, Texas, United States
Consano Clinical Research, LLC
Shavano Park, Texas, United States
CARE - Centro de Alergia y Enfermedades Respiratorias
Buenos Aires, , Argentina
CIPREC
Buenos Aires, , Argentina
Centro Médico Viamonte
Buenos Aires, , Argentina
Instituto Centenario
CABA, , Argentina
Instituto Médico Catamarca IMEC
Rosario, , Argentina
Centro de Diagnóstico y Rehabilitación (CEDIR)
Santa Fe, , Argentina
Xuanwu Hospital Capital Medical University
Beijing, , China
Peking University Third Hospital
Beijing, , China
Sichuan Provincial People's Hospital
Chengdu, , China
The Second Affiliated Hospital Chongqing Medical University
Chongqing, , China
Zhujiang Hospital
Guangzhou, , China
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, , China
The Second People's Hospital of Hefei
Hefei, , China
Jinan Central Hospital
Jinan, , China
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang Shi, , China
Zhongda Hospital Southeast University
Nanjing, , China
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, , China
The Second Hospital of Tianjin Medical University
Tianjin, , China
MUDr. Alena Vachova
České Budějovice, , Czechia
Nemocnice Cesky Krumlov
Český Krumlov, , Czechia
VASOMED Clinic
Ostrava, , Czechia
Milan Kvapil s.r.o., Diabetologicka ambulance
Prague, , Czechia
Medical Plus
Uherské Hradiště, , Czechia
InnoDiab Forschung Gmbh
Essen, , Germany
Medizentrum Essen Borbeck
Essen, , Germany
Diabetes Zentrum Wilhelmsburg
Hamburg, , Germany
AmBeNet GmbH
Leipzig, , Germany
Gemeinschaftspraxis Dr. Taeschner/Dr. Bonigut
Leipzig, , Germany
Medicover Neuroendokrinologie
Munich, , Germany
RED-Institut GmbH
Oldenburg, , Germany
Hasegawa Medicine Clinic
Chitose, , Japan
The Institute of Medical Science, Asahi Life Foundation
Chūōku, , Japan
Tokyo-Eki Center-building Clinic
Chūōku, , Japan
Fukuwa Clinic
Chūōku, , Japan
Tokuyama Clinic
Mihama-ku,Chiba City, , Japan
Medical Corporation Heishinkai ToCROM Clinic
Shinjuku-ku, , Japan
Medical Corporation Heishinkai OCROM Clinic
Suita-shi, , Japan
Olive Takamatsu Medical Clinic
Takamatsu, , Japan
Shimokitazawa Tomo Clinic
Tokyo, , Japan
Tsuchiura Medical & Health Care Center
Tsuchiura, , Japan
Noritake Clinic
Ushiku, , Japan
Medical Corporation Yuga Tsuruma Kaneshiro Diabetes Clinic
Yamato-shi, , Japan
Yokohama Minoru Clinic
Yokohama, , Japan
Puerto Rico Health and Wellness Institute
Dorado, , Puerto Rico
Isis Clinical Research Center
Guaynabo, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role: CONTACT
Phone: 1-317-615-4559
Email: [email protected]
Physicians interested in becoming principal investigators please contact
Role: CONTACT
Email: [email protected]
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-521098-14-00
Identifier Type: CTIS
Identifier Source: secondary_id
J2A-MC-GZPO
Identifier Type: OTHER
Identifier Source: secondary_id
J2A-MC-GZP1
Identifier Type: OTHER
Identifier Source: secondary_id
J2A-MC-GZP2
Identifier Type: OTHER
Identifier Source: secondary_id
27266
Identifier Type: -
Identifier Source: org_study_id